MEDICINOVA INC (MNOV) Latest Company News

Sep 30, 2026, 00:03 UTC
At 09:03 on September 30, Accel HD led special sell-side quotes with 1.49 billion yen in sell orders versus 100 million yen in buy orders, while WTI crude, F-Force G and Rentrax also saw sell quotes lowered.
Source:
- s.kabutan.jp
Sep 29, 2026, 06:58 UTC
MediciNova announced topline results of a Phase 2 clinical trial of MN-001 for hypertriglyceridemia and fatty liver disease associated with type 2 diabetes, where mean reductions in serum triglycerides and liver fat exceeded placebo but were not statistically significant.
Source:
- s.kabutan.jp
Sep 29, 2026, 00:03 UTC
On September 29, 2026, Hyugapla (7133) led special buy quotes with 6.09 billion yen in buy orders and zero sell orders, while Nidec (6594) led special sell quotes with 5.42 billion yen in sell orders against 3.15 billion yen in buy orders on the Tokyo market.
Source:
- s.kabutan.jp
Sep 28, 2026, 20:17 UTC
MediciNova Inc amended its lease with Newport Gateway Office LLC, extending the lease end date from January 31, 2027 to April 30, 2030, with rent increases effective February 1, 2027.
Sep 28, 2026, 10:00 UTC
MediciNova announced topline results from the MN-001-NATG-202 clinical trial of MN-001 (Tipelukast), which showed statistically significant increases in HDL-C and HDL-P, an early reduction in triglycerides, reduced body weight, and a numerical improvement in liver fat.
Source:
Sep 28, 2026, 00:03 UTC
On September 28, 2026, at 9:03:32 JST, 34 stocks showed special buy quotes and 5 showed special sell quotes on the Tokyo market, with Hyugapla, Disco, Akkypa, Ebara, Layered, Data Section, Nidec, ZUU, Bushiroad, Image Information, and MediciNova among the notable order imbalances.
Source:
- s.kabutan.jp
Sep 25, 2026, 23:30 UTC
MediciNova fell 12.4% to 425 yen for the week ended September 25, 2026.
Source:
- s.kabutan.jp
Sep 24, 2026, 00:03 UTC
Kioxia, SoftBank Group, Ibiden, Ebara, Metaplanet, Renesas and other Japanese stocks were quoted at special bid prices in Tokyo trading on September 24, 2026, while Fujitsu, BayCurrent, iFreeETF Nasdaq100 and MediciNova were quoted at special ask prices.
Source:
- s.kabutan.jp
Sep 18, 2026, 00:03 UTC
At 09:03 on September 18, 2026, Kikusui Electronics (6977) led special buy quotes with 7.17 billion yen in buy orders and zero sell orders, while newly listed TechnoClaf (622A) led special sell quotes with 220 million yen in sell orders.
Source:
- s.kabutan.jp
Sep 17, 2026, 06:41 UTC
Japanese stocks rose on September 17, with Kubotek leading the Tokyo Stock Exchange Standard market gainers at a 29.6% increase.
Source:
- s.kabutan.jp
Aug 19, 2026, 00:00 UTC
MediciNova Inc. announced the appointment of Yuichi Iwaki as President and Chief Executive Officer and Kazuko Matsuda as Chief Medical Officer, effective August 17, 2026, with compensation packages including base salaries and severance terms.
Aug 13, 2026, 23:51 UTC
MediciNova reported a Q2 2026 net loss of $0.05 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from a $0.07 loss a year earlier.
Source:
- zacks.com
- nasdaq.com
Jul 15, 2026, 12:00 UTC
MediciNova announced that the SEANOBI-ALS study evaluating MN-166 (ibudilast) in ALS patients achieved its target enrollment of 200 patients.
Source:
- globenewswire.com
Jun 8, 2026, 12:00 UTC
MediciNova received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering use of MN-166 with anti-PD-1 inhibitor for glioblastoma treatment.
Source:
- globenewswire.com

MNOV

At 09:03 on September 30, Accel HD led special sell-side quotes with 1.49 billion yen in sell orders versus 100 million yen in buy orders, while WTI crude, F-Force G and Rentrax also saw sell quotes lowered.

MediciNova announced topline results of a Phase 2 clinical trial of MN-001 for hypertriglyceridemia and fatty liver disease associated with type 2 diabetes, where mean reductions in serum triglycerides and liver fat exceeded placebo but were not statistically significant.

On September 29, 2026, Hyugapla (7133) led special buy quotes with 6.09 billion yen in buy orders and zero sell orders, while Nidec (6594) led special sell quotes with 5.42 billion yen in sell orders against 3.15 billion yen in buy orders on the Tokyo market.

MediciNova Inc amended its lease with Newport Gateway Office LLC, extending the lease end date from January 31, 2027 to April 30, 2030, with rent increases effective February 1, 2027.

MediciNova announced topline results from the MN-001-NATG-202 clinical trial of MN-001 (Tipelukast), which showed statistically significant increases in HDL-C and HDL-P, an early reduction in triglycerides, reduced body weight, and a numerical improvement in liver fat.

On September 28, 2026, at 9:03:32 JST, 34 stocks showed special buy quotes and 5 showed special sell quotes on the Tokyo market, with Hyugapla, Disco, Akkypa, Ebara, Layered, Data Section, Nidec, ZUU, Bushiroad, Image Information, and MediciNova among the notable order imbalances.

MediciNova fell 12.4% to 425 yen for the week ended September 25, 2026.

Kioxia, SoftBank Group, Ibiden, Ebara, Metaplanet, Renesas and other Japanese stocks were quoted at special bid prices in Tokyo trading on September 24, 2026, while Fujitsu, BayCurrent, iFreeETF Nasdaq100 and MediciNova were quoted at special ask prices.

At 09:03 on September 18, 2026, Kikusui Electronics (6977) led special buy quotes with 7.17 billion yen in buy orders and zero sell orders, while newly listed TechnoClaf (622A) led special sell quotes with 220 million yen in sell orders.

Japanese stocks rose on September 17, with Kubotek leading the Tokyo Stock Exchange Standard market gainers at a 29.6% increase.

MediciNova Inc. announced the appointment of Yuichi Iwaki as President and Chief Executive Officer and Kazuko Matsuda as Chief Medical Officer, effective August 17, 2026, with compensation packages including base salaries and severance terms.

MediciNova reported a Q2 2026 net loss of $0.05 per share, narrower than the Zacks Consensus Estimate of a $0.06 loss and improved from a $0.07 loss a year earlier.

MediciNova announced that the SEANOBI-ALS study evaluating MN-166 (ibudilast) in ALS patients achieved its target enrollment of 200 patients.

MediciNova received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering use of MN-166 with anti-PD-1 inhibitor for glioblastoma treatment.